Tidepath Get an early invite

Compared, from the FDA labels

Semaglutide vs Tirzepatide

Semaglutide (Ozempic, Wegovy) acts on one hormone receptor, GLP-1; tirzepatide (Mounjaro, Zepbound) acts on two, GIP and GLP-1. In head-to-head trials, people on tirzepatide lost more weight, both with type 2 diabetes and without it.

Side by side

OzempicWegovyMounjaroZepbound
Medicine in itSemaglutideSemaglutideTirzepatideTirzepatide
Made byNovo NordiskNovo NordiskEli LillyEli Lilly
Receptors it acts onOne: the GLP-1 receptorOne: the GLP-1 receptorTwo: the GIP and GLP-1 receptorsTwo: the GIP and GLP-1 receptors
Approved forType 2 diabetes in adults: blood sugar control, and lowering the risk of heart attack, stroke or cardiovascular death in those with heart disease, and of kidney disease getting worse in those with chronic kidney diseaseWeight: losing excess weight and keeping it off, for adults and children 12 and older with obesity, and adults with overweight and a weight-related condition. Also lowering the risk of heart attack, stroke or cardiovascular death in adults with heart disease, and (the injection) a liver disease, MASH, with moderate to advanced scarringType 2 diabetes: blood sugar control in adults and children 10 and older, and lowering the risk of heart attack, stroke or cardiovascular death in adults at high riskWeight: losing excess weight and keeping it off, for adults with obesity, or overweight with a weight-related condition. Also moderate to severe obstructive sleep apnea in adults with obesity
How it's takenAn injection once a weekAn injection once a week, or a tablet once a dayAn injection once a weekAn injection once a week
Starting dose0.25 mg a week for 4 weeks, then 0.5 mgInjection: 0.25 mg a week for 4 weeks. Tablet: 1.5 mg a day for 30 days2.5 mg a week2.5 mg a week for 4 weeks, then 5 mg
Dose it builds up to0.5 mg, 1 mg or 2 mg a week, raised if more blood sugar control is neededUsually 2.4 mg a week (injection), or 25 mg a day (tablets)Up to 15 mg a week, in 2.5 mg steps if more blood sugar control is needed (up to 10 mg for children)5 mg, 10 mg or 15 mg a week for weight; 10 or 15 mg for sleep apnea
Half-lifeAbout 1 weekAbout 1 weekAbout 5 daysAbout 5 to 6 days
If you miss a doseTake it within 5 days; after that, skip itInjection: goes by your next dose. More than 2 days away, take it; less, skip itTake it within 4 days (96 hours); after that, skip itTake it within 4 days (96 hours); after that, skip it

Both are weekly injections, both are approved for type 2 diabetes (as Ozempic and Mounjaro) and for weight (as Wegovy and Zepbound), and both carry the same boxed warning about thyroid tumors seen in animal studies.

Doses are what each label sets out. Your prescriber decides yours.

In head-to-head trials

These trials gave people one medicine or the other and compared them directly.

SURMOUNT-5

In SURMOUNT-5, published in the New England Journal of Medicine in 2025, 751 adults with obesity but without type 2 diabetes took the highest dose they could tolerate of tirzepatide (10 or 15 mg, the medicine in Zepbound) or semaglutide (1.7 or 2.4 mg, the medicine in Wegovy), once a week for 72 weeks.

Weight fell by an average of 20.2% on tirzepatide and 13.7% on semaglutide. Waist size fell by 18.4 cm and 13.0 cm.

The most common side effects in both groups were stomach-related, mostly mild to moderate, and mostly while the dose was being raised.

Everyone knew which medicine they were taking (an open-label trial), and the trial was funded by Eli Lilly, which makes tirzepatide.

SURPASS-2

In SURPASS-2, a 40-week trial in Mounjaro's FDA label, 1,879 adults with type 2 diabetes already taking metformin were given Mounjaro 5, 10 or 15 mg, or semaglutide 1 mg (the medicine in Ozempic), once a week.

HbA1c, a measure of average blood sugar, fell by 2.0, 2.2 and 2.3 points on Mounjaro 5, 10 and 15 mg, and by 1.9 on semaglutide 1 mg. The label says the 10 mg and 15 mg results were statistically significantly better than semaglutide's.

Weight fell by 7.6, 9.3 and 11.2 kg on Mounjaro 5, 10 and 15 mg, and by 5.7 kg on semaglutide 1 mg.

The trial used semaglutide 1 mg. Ozempic's label now also allows 2 mg, which this trial didn't test.

Questions about semaglutide and tirzepatide

What's the difference between semaglutide and tirzepatide?

Semaglutide (Ozempic, Wegovy) acts on one hormone receptor, GLP-1; tirzepatide (Mounjaro, Zepbound) acts on two, GIP and GLP-1. In head-to-head trials, people on tirzepatide lost more weight, both with type 2 diabetes and without it.

More detail and sources

Both are weekly injections, both are approved for type 2 diabetes (as Ozempic and Mounjaro) and for weight (as Wegovy and Zepbound), and both carry the same boxed warning about thyroid tumors seen in animal studies.

Is tirzepatide better than semaglutide for weight loss?

In head-to-head trials, people on tirzepatide lost more weight. Weight fell by an average of 20.2% on tirzepatide and 13.7% on semaglutide. Waist size fell by 18.4 cm and 13.0 cm.

More detail and sources

In SURMOUNT-5, published in the New England Journal of Medicine in 2025, 751 adults with obesity but without type 2 diabetes took the highest dose they could tolerate of tirzepatide (10 or 15 mg, the medicine in Zepbound) or semaglutide (1.7 or 2.4 mg, the medicine in Wegovy), once a week for 72 weeks.

In SURPASS-2, a 40-week trial in Mounjaro's FDA label, 1,879 adults with type 2 diabetes already taking metformin were given Mounjaro 5, 10 or 15 mg, or semaglutide 1 mg (the medicine in Ozempic), once a week.

Which one suits you depends on your health, your other medicines and your coverage, and is a decision for you and your prescriber.

Are semaglutide and tirzepatide the same drug?

No. They're different medicines from different makers: semaglutide from Novo Nordisk and tirzepatide from Eli Lilly.

Can I switch from semaglutide to tirzepatide?

Only with your prescriber. None of the four labels gives a dose for switching from one of these brands to another, so your prescriber chooses where the new medicine starts.

More detail and sources

Don't take them together. Wegovy's and Zepbound's labels say they're not recommended with any other GLP-1 medicine.

Sources

Last reviewed

For information, not medical advice. Your prescriber and your product's label come first.

Keep your shots, food and training in one place.

Tidepath is an iPhone app for people on a GLP-1, whichever one you take. It isn't in the App Store yet. Leave your email for an early invite, and tips for your first month. See how the app works